Abstract 4-Methylumbelliferone (4-MU) inhibits hyaluronic acid (HA) synthesis and is approved in Europe for treatment of biliary spasm. 4-MU administration reduces perineuronal net (PNN) levels, and enzymatic degradation of PNNs in mouse models of Alzheimer’s disease (AD) attenuates memory impairment. Although 4-MU has therapeutic efficacy in rodent models of fibrosis and cancer, it has not been examined in an Alzheimer’s model.
Katherine Conant
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Katherine
Contact Katherine, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack